Tiziana Life Sciences Ltd., which is developing the intranasal fully human anti-CD3 monoclonal antibody foralumab for neurological indications, has reported results from studies using a nasal anti-CD3 ...
Spinal cord compression (SCC) occurs in 5% to 30% of the oncology population and affects patient function, comfort, and general quality of life. Patients with lung cancer, breast cancer ...
Dr. Saef Izzy, Associate Professor of Neurology at Harvard Medical School, commented, “Treatment with nasal anti-CD3 not only dampened microglial activation but also led to marked improvements in ...